Company intelligence / Profile preview

Orthobond

Princeton, New Jersey, United Statesorthobond.com ↗

Ownership: Private
Development stage: Other

Overview

Orthobond has developed a proprietary antimicrobial nanosurface technology that can be permanently bound to metallic and polymeric surfaces, killing bacteria, viruses, and fungi by mechanically rupturing pathogens without antibiotics or eluting chemicals. The company is seeking its first FDA clearance for use on implantable medical devices. No clinical trial results are published yet; the focus is on regulatory approval and commercialization.

Therapeutic areas: Infectious Diseases
Modalities: DeviceNon-pharmacological therapy (antimicrobial nanosurface coating)
Industry: Implantable Medical Devices

Partnerships

Partnerships with major medical-device manufacturers for application of the surface treatment to new implants/devicesCollaborations with leading chemical industry companies

Beyond the preview

Go deeper on Orthobond.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orthobond.

Explore the full profile